| meta-analysis | Q815382 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S10147-017-1231-X |
| P698 | PubMed publication ID | 29289981 |
| P50 | author | Xiu-Jun Cai | Q87981158 |
| P2093 | author name string | Donghun Shin | |
| Fangqiang Wei | |||
| P2860 | cites work | Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement | Q27860537 |
| Untangling the ErbB signalling network | Q27860884 | ||
| Practical methods for incorporating summary time-to-event data into meta-analysis | Q28131754 | ||
| Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer | Q28240089 | ||
| Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer | Q28298328 | ||
| Quantitative synthesis in systematic reviews | Q29614894 | ||
| Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer | Q29616236 | ||
| Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group | Q29619344 | ||
| Risk of severe rash in cancer patients treated with EGFR tyrosine kinase inhibitors: a systematic review and meta-analysis | Q30248499 | ||
| Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial. | Q30317428 | ||
| Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study. | Q33392786 | ||
| A phase II trial of gemcitabine, irinotecan and panitumumab in advanced cholangiocarcinoma | Q33411061 | ||
| Cetuximab, gemcitabine and capecitabine in patients with inoperable biliary tract cancer: a phase 2 study | Q85640601 | ||
| Biliary tract cancers. | Q33760399 | ||
| Phase II study of gemcitabine, oxaliplatin in combination with panitumumab in KRAS wild-type unresectable or metastatic biliary tract and gallbladder cancer. | Q33994406 | ||
| Phase II study of erlotinib in patients with advanced biliary cancer | Q33997258 | ||
| Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium study | Q34048813 | ||
| Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck | Q34287207 | ||
| Mechanisms of cutaneous toxicities to EGFR inhibitors. | Q34567916 | ||
| Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial | Q34614245 | ||
| Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer | Q34618537 | ||
| Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis. | Q34637757 | ||
| Correlation of cetuximab-induced skin rash and outcomes of solid tumor patients treated with cetuximab: a systematic review and meta-analysis. | Q35228425 | ||
| Antibiotic prophylaxis for skin toxicity induced by antiepidermal growth factor receptor agents: a systematic review and meta-analysis | Q36026706 | ||
| Supportive care treatments for toxicities of anti-egfr and other targeted agents | Q36040625 | ||
| Cutaneous side-effects of kinase inhibitors and blocking antibodies | Q36181698 | ||
| Anti-inflammatory activity of tetracyclines | Q36790231 | ||
| Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial | Q36892840 | ||
| Relationship between skin rash and outcome in non-small-cell lung cancer patients treated with anti-EGFR tyrosine kinase inhibitors: a literature-based meta-analysis of 24 trials | Q38026292 | ||
| The predictive role of skin rash with cetuximab and panitumumab in colorectal cancer patients: a systematic review and meta-analysis of published trials | Q38074290 | ||
| An open-label single-arm, phase II trial of zalutumumab, a human monoclonal anti-EGFR antibody, in patients with platinum-refractory squamous cell carcinoma of the head and neck | Q38432573 | ||
| Combination of gemcitabine and cetuximab in patients with advanced cholangiocarcinoma: a phase II study of the Belgian Group of Digestive Oncology | Q38445683 | ||
| Placebo-controlled phase II study of vitamin K3 cream for the treatment of cetuximab-induced rash. | Q38961183 | ||
| Cancer Statistics, 2017. | Q39038674 | ||
| Role of ErbB/HER family of receptor tyrosine kinases in cholangiocyte biology. | Q39410914 | ||
| Phase II marker-driven trial of panitumumab and chemotherapy in KRAS wild-type biliary tract cancer | Q39647813 | ||
| Correlation Between the Severity of Cetuximab-Induced Skin Rash and Clinical Outcome for Head and Neck Cancer Patients: The RTOG Experience. | Q39745151 | ||
| Identification of a key pathway required for the sterile inflammatory response triggered by dying cells | Q40119160 | ||
| Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: A randomized phase 2 trial (Vecti-BIL study). | Q40352514 | ||
| TACTIC: a multicentre, open-label, single-arm phase II trial of panitumumab, cisplatin, and gemcitabine in biliary tract cancer | Q40686537 | ||
| Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition | Q43843455 | ||
| A phase 2 randomized trial of paclitaxel and carboplatin with or without panitumumab for first-line treatment of advanced non-small-cell lung cancer | Q46369893 | ||
| Erlotinib for advanced non-small-cell lung cancer in the elderly: an analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. | Q46604163 | ||
| Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption | Q46874379 | ||
| Cetuximab plus gemcitabine-oxaliplatin (GEMOX) in patients with refractory advanced intrahepatic cholangiocarcinomas | Q46891324 | ||
| Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer. | Q48020812 | ||
| A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer | Q48126437 | ||
| Predictive Value of Early Skin Rash in Cetuximab-Based Therapy of Advanced Biliary Tract Cancer. | Q48214785 | ||
| Gemcitabine, capecitabine and oxaliplatin with or without cetuximab in advanced biliary tract carcinoma. | Q53347236 | ||
| Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study. | Q53393758 | ||
| SnapShot: EGFR signaling pathway | Q80111317 | ||
| Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies | Q80557811 | ||
| P433 | issue | 3 | |
| P304 | page(s) | 443-451 | |
| P577 | publication date | 2017-12-30 | |
| P1433 | published in | International Journal of Clinical Oncology | Q15758148 |
| P1476 | title | Incidence, risk and prognostic role of anti-epidermal growth factor receptor-induced skin rash in biliary cancer: a meta-analysis | |
| P478 | volume | 23 |
Search more.